YARDLEY, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced it has successfully completed recruitment in the first of two pivotal clinical trials to evaluate the safety and efficacy of XHANCE® (fluticasone propionate) nasal spray as a treatment for patients with chronic sinusitis (CS).
- Today we are announcing completion of recruitment in the first of our pivotal CS trials, stated Ramy Mahmoud, M.D., MPH, President and Chief Operating Officer of Optinose.
- Our clinical team is now focusing all of its recruitment effort on the second of our two pivotal CS trials, and we expect to complete enrollment in that trial before year-end.
- The completion of recruitment for this trial keeps us on track to have top-line results in the first quarter of 2022, said CEO Peter Miller.
- If successful, XHANCE may be the first FDA-approved drug product for chronic sinusitis.